Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AVEO and Merck extend oncology collaboration
The collaboration is focused on identifying genetic profiles that correlate with drug response to more effectively guide the clinical and market development of Merck’s cancer compounds. Under the
The collaboration is focused on identifying genetic profiles that correlate with drug response to more effectively guide the clinical and market development of Merck’s cancer compounds. Under the
The trial enrolled 160 patients with the disorder in 11 centers across the US. Patients in the AT-001 arm of the trial received 25mg of AT-001 daily for
While the research, initiated in August 2003, was initially focused on one class of compounds, the two companies have agreed to broaden the field of investigation based on
The phase II study in metastatic breast cancer is an open label, multicenter study being managed by US Oncology, a healthcare services network focused on cancer treatment and
The 100-patient clinical trial is designed to assess the product’s safety and feasibility in increasing the incidence of complete wound healing and reducing the incidence of subsequent amputations
In connection with the closing of this acquisition, DOR will issue the stockholders of Gastrotech $9 million in shares of DOR common stock. A further $30 million in
Since many hypertensive patients require combination therapy in order to reach optimal blood pressure levels, combining two effective agents into a single drug product may simplify multi-drug treatment
The study of 3,600 patients on hemodialysis, found no reduction in S aureus types 5 and 8 infections in the Staphvax group as compared to the placebo group.
Under the terms of the collaboration, AstraZeneca will evaluate a number of prostate cancer drug targets discovered by Caprion. AstraZeneca will obtain exclusive, worldwide rights to develop and
At present Tamiflu is believed to be the most effective treatment against avian flu. The product was originally co-developed with the US firm Gilead Sciences and is indicated